Activity and research directory projects
The directory lists antimicrobial resistance (AMR) activities and research and displays whether they are in progress or completed. Use the filters and search to help refine your query.5 activities or research projects found
- 18 August 2020Our team is developing a One Health surveillance system for Fiji to identify AMR hot spots. The system will help inform intervention strategies, increase national research capacity across multiple sectors, develop risk and socio-economic evaluation frameworks, recommend sustainable AMR management policies, and educate the public. This is funded by the Australian Centre for International Agricultural Research and the Department of Foreign Affairs and Trade Indo-Pacific Centre for Health Security.CSIRO, UTS, UniSA, Fiji Ministry of Health and Medical Services, Fiji Ministry of Agriculture, Fijian National Antimicrobial Resistance Committee, and Fiji National University.
- 2 August 2019The two main objectives of this project is: 1) to engineer micro- and nano-surfaces with enhanced anti-microbial properties and 2) to develop novel technologies to include such functional micro and nano-surfaces on "real-life" objects, overcoming the limitation of micro and nanotechnologies to small areas and flat surfaces.Monash University
- 29 June 2019Glycopeptide antibiotics – which include vancomycin – are last-resort antibiotics used in the clinic to treat serious Gram-positive bacterial infections. In this project, my team are utilising a novel chemo-enzymatic formation route that we have pioneered to generate and explore the properties of new vancomycin derivatives. This will allow us to explore the structure/ function relationships of these crucial antibiotics and to overcome growing bacterial resistance against these compounds.Monash University
- 29 June 2019In this project, my team is developing a new approach to tackling antimicrobial resistance that exploits alternate mechanisms to overcome bacterial infections through augmentation of host immune responses and removal of bacterial evasion mechanisms. Our simultaneous “drug-immune” therapies will provide highly synergistic bacterial killing utilising existing antibiotic therapeutics, thus underlining the feasibility of future clinical application of such approaches.Monash University
- 27 June 2019We are working with clinicians in the Center for Innovative Phage Applications and Therapeutics at the University of California in San Diego. Phage therapy is frontier medicine, and has FDA approval for use in hospitals in the USA. Isolating clinically-effective "cocktails" is a challenge that can only be met by collaboration between research scientists trained in phage biology (Monash) and clinicians with experience in clinical deployment (UCSD).Monash University.
University of California in San Diego.